30 December 2024 in Yakut Medical Journal
Multiple primary malignant tumors are independent occurrence and development of two or more neoplasms in one patient. In this case, not only different organs of different systems can be affected, but also paired organs, as well as one organ multicentrically. Carcinogenesis is based on a multistage process of changes, malignant transformation and progression, which includes DNA damage and dysfunction of the immune system. Damage to certain parts of genes involved in mitosis, cell death or DNA repair is reflected in an increase in the mutation load. After accumulation of a sufficient number of mutations, control over cell function is disrupted, which leads to the development of cancer. In recent years, an increase in the frequency of multiple primary neoplasms has been noted. The review presents the main risk factors that to one degree or another affect the development of polyneoplasia. Keywords: multiple primary malignant neoplasms, polyneoplasia, risk factors
14 July 2025 in Bulletin of Siberian Medicine
Aim. To analyze the structure of deaths from sporadic metachronous primary multiple malignant neoplasms in 2017–2023 in a multidisciplinary inpatient facility.Materials and methods. The study included 2,394 fatal cases of patients hospitalized in a multidisciplinary inpatient facility for emergency medical care. In 2017–2023, 29 metachronous primary multiple malignant neoplasms were identified, which was 1.3% of the total number of fatal outcomes and 11% of malignant neoplasms. The median age of patients was 72.0 (69.0–82.0) years. We examined the protocols of pathological studies of autopsy material of patients hospitalized in the inpatient facility of multidisciplinary clinics of Siberian State Medical University. In patients with metachronous primary multiple malignant neoplasms, the nosological structure, stage of the process, histological form of the neoplasm, the period between the diagnosis of the first and second malignant tumor, and the immediate cause of death were analyzed. Statistical processing of the results was carried out using the Statistica 10.0 software package.Results. The first tumor was most often caused by squamous cell skin cancer (21%) or invasive ductal carcinoma of the breast (17.5%). The interval between the diagnosis of the first and second tumor was 72.0 (48.0–96.0) months. All patients received definitive treatment for the first tumor without progression. The second metachronous tumors were verified in an advanced stage in 72% of cases and caused the death of patients. Most often (17.5%) these were diffuse gastric cancer.Conclusion. Metachronous primary multiple malignant tumors can occur long after the first ones (about 6 years), often in advanced forms (in this case, tumors verified exclusively postmortem – 69%), being the cause of death of patients. The most common first tumors in sporadic metachronous primary multiple malignant neoplasms are recurrent squamous cell skin cancer and ductal carcinoma of the mammary gland. The main target organ for the development of oncopathology is the stomach.
11 April 2025 in Bulletin of Siberian Medicine
Aim. To study the features of the expression of the integrin subunit β4 in primary tumor tissue depending on the clinical and morphological parameters of breast cancer. Materials and methods. We examined biopsy samples from 49 patients with T1–4N0–3M0 breast cancer; the median age was 51.0 [44.0; 60.0] years. Patients did not receive neoadjuvant therapy. Surgical intervention involved resection of the mammary gland with axillary lymph node dissection or radical mastectomy. The expression of markers of estrogen receptor, progesterone receptor, c-erB-2 (Her2/neu), Ki67, CD104 (integrin subunit β4) was assessed using immunohistochemistry. Statistical processing of the results was carried out using the Statisctica 10.0 software package. Results. In the group of patients with N3 degree, cases with positive cytoplasmic/membrane colocalization of integrin subunit β4 expression were more frequently detected (45%), compared with observations where no such expression was found (8%; p = 0.002). Conclusion. Positive cytoplasmic/membrane colocalization of integrin subunit β4 expression is associated with the prevalence of lymphatic metastasis, which corresponds to N3 degree.
21 September 2026 in Siberian journal of oncology
Objective: to study the expression of alpha-6/beta-4 integrin and laminin-332 in lymph node-positive luminal a breast cancer. Material and Methods. Surgical specimens from 110 patients with luminal a breast cancer (T1–2N0–3M0), who were treated at Tomsk Cancer Research Institute from 2016 to 2022, were analyzed. All patients were divided into two groups: those without lymph node metastases (n=81) and those with lymph node metastases (n=29). The immunohistochemical study was performed according to a standard procedure using antibodies to integrin alpha-6 subunit (ITGA6), integrin beta-4 subunit (ITGB4) and gamma-2 subunit of laminin-332 (LAMG2). Histological samples were digitized using whole-slide scanners. The scanned slices were analyzed using SlideViver V2.8 and QuantCenter software tools. Results. The positive expression of ITGB4 (66 % and 19 %; χ2=22.088; p<0.001) and LAMG2 (86 % and 7 %; χ2=65.514; p<0.001) in tumor cells of the primary tumor was more often detected in patients with lymph nose metastases than in patients without lymph node metastases. Tumor cells positive for ITGA6, ITGB4 and LAMG2 showed higher expression in lymph node metastases than in primary tumors. Conclusion. The expression of alpha-6/beta-4 integrin and laminin-332 correlates with lymph node metastasis, and the expression of gamma-2 subunit of lamnin-332 can serve as a marker for lymph node metastasis.
23 July 2026 in Bulletin of Siberian Medicine
Despite advances in modern oncology, in Russia, 36% of gastric cancers are detected at an advanced stage, with a one-year mortality rate of 39.6%. One of the most common causes of death from gastric cancer is peritoneal carcinomatosis. Synchronous peritoneal carcinomatosis is diagnosed in 18–26% of cases. Metachronous carcinomatosis occurs in 7–39% of patients 8.5–26 months after the primary tumor is removed. To date, there are no effective treatments for peritoneal carcinomatosis. Tumors accompanied by peritoneal carcinomatosis are often resistant to systemic chemotherapy. Cytoreductive surgeries and intraperitoneal chemotherapy are not always possible or successful for all patients.This review focuses on analyzing the molecular and genetic mechanisms of peritoneal carcinomatosis in gastric cancer and presents an original hypothesis suggesting that peritoneal carcinomatosis occurs when tumor cells acquire the ability to autonomously exist in a matrix-independent state in the ascitic fluid without undergoing apoptosis (anoeucsis). Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, 10,025 scientific papers were identified, of which 228 English-language and 323 Russian-language publications met the analysis criteria. Twenty-nine articles (including four Russian-language ones) relevant to the topic of this review were included in the review. It is assumed that the identification of key molecules associated with the matrixindependent existence of tumor cells could serve as the basis for the development of technologies for predicting peritoneal carcinomatosis, as well as for the development of new targeted therapy for metastatic gastric cancer.
1 October 2026 in Bulletin of Siberian Medicine
Lymphangitic carcinomatosis is one of the most severe forms of tumor progression. It is characterized by the massive spread of tumor emboli, composed of cells with reduced adhesive capacity to the endothelium, through the lymphatic vessels. Using the PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) guidelines, 394 scientific papers were screened. Of those, 292 English-language publications met the criteria for analysis. A total of 39 articles (including three in Russian) relevant to the topic of this review were included. Due to the highly diverse localization of lymphangitic carcinomatosis and its polymorphic symptoms, diagnosis remains challenging and is associated with the risk of erroneous and often delayed decision-making. Data on lymphangitic carcinomatosis are still scarce, and its developmental mechanisms are not fully understood. However, systematizing knowledge about its possible clinical and morphological manifestations and studying the molecular and genetic mechanisms of its development could serve as a basis for identifying key prognostic markers and developing targeted therapies for this currently prognostically unfavorable form of tumor progression.